NIATx/MAT Academy for Opioid Addiction

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Washington State Healthcare Authority, Olympia, WA
Opioid Addiction+2 More
NIATx/MAT Academy - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to expand access to medications for opioid use disorder (MOUD) in specialty addiction programs in Washington State. Sixty-four addiction treatment programs will participate in an adaptive implementation strategy trial that uses a stagewise implementation-to-target (stepped "care" type) approach whereby organizations engage in increasingly intensive implementation strategies as needed. Organizations are moved to a follow-up/sustainment arm once they have met the implementation targets described below. The design also includes an external comparator arm, which consists of 510 addiction treatment programs that are not participating in the study and will mimic as study controls. The sequence of implementation strategies are: Enhanced Monitoring and Feedback NIATx/MAT Academy Randomization to either NIATx Internal Facilitation or NIATx External Facilitation Assignment to NIATx External Facilitation if outcome targets are not achieved in the NIATx Internal Facilitation arm Implementation targets are: Reach - At least 75% of patients with opioid use disorder (OUD) receiving MOUD for three consecutive months Adoption - At least 1 integrated MOUD prescriber actively prescribing MOUD Implementation - a total score ≥ 4 on the Integrating Medications for Addiction Treatment (IMAT) Index. Contextual moderators and mediators of performance on target outcomes as a function of the implementation strategy step will be examined, as will the costs associated with participation in the sequence of implementation strategies.

Eligible Conditions

  • Opioid Addiction

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: Months 1,7,14,24,34,46

Month 1
Cost of implementation
Engagement in implementation
Months 1,7,14,24,34,46
Contextual determinants
Implementation - Integrating Medications for Addiction Treatment (IMAT) Index
Implementation Leadership
Implementation climate
Months 7,14,24,34,46
Fidelity
Month 1
Adoption
Effectiveness
Reach

Trial Safety

Safety Progress

1 of 3

Trial Design

5 Treatment Groups

Path 2
1 of 5
Path 3
1 of 5
Path 5
1 of 5
Path 4
1 of 5
Path 1
1 of 5
Experimental Treatment

64 Total Participants · 5 Treatment Groups

Primary Treatment: NIATx/MAT Academy · No Placebo Group · N/A

Path 2Experimental Group · 2 Interventions: Enhanced Monitoring and Feedback (EMF), NIATx/MAT Academy · Intervention Types: Other, Other
Path 3Experimental Group · 3 Interventions: Enhanced Monitoring and Feedback (EMF), NIATx-External Facilitation (NIATx-EF), NIATx/MAT Academy · Intervention Types: Other, Other, Other
Path 5Experimental Group · 4 Interventions: NIATx-Internal Facilitation (NIATx-IF), Enhanced Monitoring and Feedback (EMF), NIATx-External Facilitation (NIATx-EF), NIATx/MAT Academy · Intervention Types: Other, Other, Other, Other
Path 4Experimental Group · 3 Interventions: NIATx-Internal Facilitation (NIATx-IF), Enhanced Monitoring and Feedback (EMF), NIATx/MAT Academy · Intervention Types: Other, Other, Other
Path 1
Other
Experimental Group · 1 Intervention: Enhanced Monitoring and Feedback (EMF) · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: months 1,7,14,24,34,46
Closest Location: Washington State Healthcare Authority · Olympia, WA
Photo of washington 1Photo of washington 2Photo of washington 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Opioid Addiction
0 CompletedClinical Trials

Who is running the clinical trial?

University of Wisconsin, MadisonOTHER
1,052 Previous Clinical Trials
2,559,847 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,203 Previous Clinical Trials
5,610,415 Total Patients Enrolled
4 Trials studying Opioid Addiction
1,001 Patients Enrolled for Opioid Addiction
Stanford UniversityLead Sponsor
2,130 Previous Clinical Trials
35,668,846 Total Patients Enrolled
1 Trials studying Opioid Addiction
500 Patients Enrolled for Opioid Addiction
Washington State Health Care AuthorityUNKNOWN
James H Ford II, PhDPrincipal InvestigatorUniversity of Wisconsin, Madison
1 Previous Clinical Trials
2,942 Total Patients Enrolled
Mark McGovern, PhDPrincipal InvestigatorStanford University

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.